Application of low-intensity anticoagulation after On-X mechanical aortic valve replacement

Abstract Objective To explore the safety and efficacy of low-intensity anticoagulation in patients after On-X mechanical aortic valve replacement. Methods A total of 104 patients undergoing aortic valve replacement in Cardiac Surgery Department of Sichuan Provincial People’s Hospital from December 2...

Full description

Saved in:
Bibliographic Details
Main Authors: Kun Zou, Dachuang Wei, Bo Xiang, Tao Yu, Keli Huang, Shengzhong Liu
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Journal of Cardiothoracic Surgery
Subjects:
Online Access:https://doi.org/10.1186/s13019-024-03215-7
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective To explore the safety and efficacy of low-intensity anticoagulation in patients after On-X mechanical aortic valve replacement. Methods A total of 104 patients undergoing aortic valve replacement in Cardiac Surgery Department of Sichuan Provincial People’s Hospital from December 2018 to December 2021 were randomly divided into low-intensity anticoagulant (INR:1.5-2.0) and high-intensity anticoagulant (INR:2.0-2.5) to compare the incidence of adverse events related to postoperative anticoagulation between the two groups. Results Fifty-three patients were included in the low-intensity anticoagulation group (INR 1.5-2.0), and 51 patients were included in the high-intensity group (2.0-2.5). There was no significant difference in baseline data and surgical index between the two groups (P > 0.05); there were statistically significant differences in PT, INR and bleeding events (P < 0.05), but no significant difference in embolic events (P > 0.05). Conclusion For patients requiring On-X mechanical aortic valve replacement who have no risk factors for thromboembolism, it is appropriate to control the INR in the target range 1.5-2.0, which can reduce the incidence of bleeding adverse events and significantly improve the quality of life, without increasing the risk of thromboembolic adverse events.
ISSN:1749-8090